References

Leprosy

10.1038/s41572-024-00575-1 · 2024 · External reference

Global leprosy (Hansen disease) update, 2024: Beyond zero cases - what elimination of leprosy really means

2025 · External reference

Epidemiological characteristics of leprosy reactions: 15 years experience from North India

10.1489/1544-581x(2004)072<0125:ecolry>2.0.co;2 · 2004 · External reference

Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients

10.1371/journal.pntd.0005725 · 2017 · External reference

The incidence of erythema nodosum leprosum in India: a retrospective follow-up of the INFIR cohort

10.47276/lr.89.3.321 · 2018 · External reference

Clinical course of erythema nodosum leprosum: An 11-year cohort study in Hyderabad, India

10.4269/ajtmh.2006.74.868 · 2006 · External reference

A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction

2013 · External reference

ENLIST 1: An International multi-centre cross-sectional study of the clinical features of erythema nodosum leprosum

10.1371/journal.pntd.0004065 · 2015 · External reference

Health-related quality of life amongst people affected by erythema nodosum leprosum in Bangladesh: A cross sectional study

10.47276/lr.88.4.488 · 2017 · External reference

Health-related quality of life associated with erythema nodosum leprosum in Purulia, West Bengal, India

10.47276/lr.91.1.100 · 2020 · External reference

The impact of erythema nodosum leprosum on health related quality of life in Rio de Janeiro

10.47276/lr.88.4.499 · 2017 · External reference

Household costs of leprosy reactions (ENL) in rural India

10.1371/journal.pntd.0003431 · 2015 · External reference

A systematic review of immunological studies of erythema nodosum leprosum

10.3389/fimmu.2017.00233 · 2017 · External reference

Regulatory T cells in erythema nodosum leprosum maintain anti-inflammatory function

10.1371/journal.pntd.0010641 · 2022 · External reference

The effects of prednisolone treatment on cytokine expression in patients with erythema nodosum leprosum reactions

10.3389/fimmu.2018.00189 · 2018 · External reference

Clinico-pathological features of erythema nodosum leprosum: A case-control study at ALERT hospital, Ethiopia

10.1371/journal.pntd.0006011 · 2017 · External reference

Unresolved reference

2017 · External reference

The mortality associated with erythema nodosum leprosum in Ethiopia: A retrospective hospital-based study

10.1371/journal.pntd.0002690 · 2014 · External reference

A systematic review of adverse effects associated with systemic corticosteroids in the management of leprosy

External reference

Retrospective study of the morbidity associated with erythema nodosum leprosum in Brazilian leprosy patients

10.47276/lr.90.1.68 · 2019 · External reference

Erythema nodosum leprosum in Nepal: A retrospective study of clinical features and response to treatment with prednisolone or thalidomide

10.47276/lr.79.3.254 · 2008 · External reference

Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: A five-year retrospective analysis from a leprosy referral centre in India

10.1371/journal.pntd.0008678 · 2020 · External reference

Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: A randomized study

10.1111/j.1440-0960.2009.00534.x · 2009 · External reference

A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

10.1093/rheumatology/kes001 · 2012 · External reference

Application and pharmacological mechanism of methotrexate in rheumatoid arthritis

10.1016/j.biopha.2022.113074 · 2022 · External reference

2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis

10.1002/acr.24596 · 2021 · External reference

Methotrexate in resistant juvenile rheumatoid arthritis

1992 · External reference

British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016

10.1111/bjd.14816 · 2016 · External reference

Efficacy and safety of prednisolone monotherapy versus prednisolone plus methotrexate in erythema nodosum leprosum (type 2 lepra reaction)

10.1097/jd9.0000000000000133 · 2020 · External reference

International workshop on erythema nodosum leprosum (ENL) - consensus report; the formation of ENLIST, the ENL International STudy group

10.47276/lr.83.4.396 · 2012 · External reference

Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: A double-blind randomised clinical trial

10.1136/bmjopen-2020-037700 · 2020 · External reference

A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL Severity Scale

10.1371/journal.pntd.0005716 · 2017 · External reference

Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use

1994 · External reference

SF-36 health survey manual and interpretation guide

1993 · External reference

Interventions for erythema nodosum leprosum. A cochrane review

10.47276/lr.80.4.355 · 2009 · External reference

Effectiveness and safety of clofazimine and pentoxifylline in type 2 lepra reaction: A double-blind, randomized, controlled study

10.1111/ijd.12793 · 2015 · External reference

Comparison of efficacy and safety of ciclosporin to prednisolone in the treatment of erythema nodosum leprosum: Two randomised, double blind, controlled pilot studies in Ethiopia

10.1371/journal.pntd.0004149 · 2016 · External reference

Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study. (GrIDIST) G d’infectiologie en dermatologie et des infections sexuellement transmissibles, editor

10.1371/journal.pntd.0011238 · 2023 · External reference

Methotrexate an old drug with new tricks

10.3390/ijms20205023 · 2019 · External reference

Treatment of recurrent erythema nodosum leprosum with infliximab

10.1056/nejmc052955 · 2006 · External reference

Treatment of severe refractory erythema nodosum leprosum with tumor necrosis factor inhibitor Etanercept

10.1016/j.ijmyco.2016.02.002 · 2016 · External reference

Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept

10.1093/cid/ciq213 · 2011 · External reference

Can etanercept be an option in management of recurrent steroid-dependent erythema nodosum leprosum? A retrospective study of six patients

10.25259/ijdvl_726_20 · 2022 · External reference

Biologics in leprosy: A systematic review and case report

10.4269/ajtmh.19-0616 · 2020 · External reference

Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis

10.1016/s0140-6736(98)02197-7 · 1998 · External reference

The role of thalidomide in the management of erythema nodosum leprosum

10.47276/lr.78.3.197 · 2007 · External reference

Access to thalidomide

10.47276/lr.94.3.186 · 2023 · External reference

Methotrexate treatment for type 1 (reversal) leprosy reactions

10.1086/518699 · 2007 · External reference

Mycobacteria.

2016 · External reference

Cytokine and protein markers of leprosy reactions in skin and nerves: baseline results for the North Indian INFIR cohort

2011 · External reference

Efficacy and gastrointestinal tolerability of methotrexate in late-onset rheumatoid arthritis patients: A prospective cohort study

10.1186/s43166-023-00178-w · 2023 · External reference

Low-dose methotrexate and serious adverse events among older adults with chronic kidney disease

10.1001/jamanetworkopen.2023.45132 · 2023 · External reference

Adverse effects of low-dose methotrexate: A randomized trial

10.7326/m19-3369 · 2020 · External reference

Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study

10.1093/rheumatology/keab917 · 2022 · External reference